Mycophenolate Mofetil Capsules and Rapamune (Sirolimus Tablets)
Determining the interaction of Mycophenolate Mofetil Capsules and Rapamune (Sirolimus Tablets) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using mycophenolate mofetil together with sirolimus may increase the effects of mycophenolate mofetil. Notify your doctor immediately if you develop fever or chills, a sore throat, unusual bleeding or bruising, mouth sores, abdominal pain, pale stools, or darkened urine. These symptoms could be early signs of dangerous side effects. Mycophenolate mofetil may also cause nausea, vomiting, diarrhea, and unusual bleeding or bruising. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with sirolimus may increase the plasma concentrations of mycophenolic acid. The mechanism of interaction is unknown. In 13 kidney transplant patients receiving concomitant therapy with sirolimus, the mycophenolic acid systemic exposure (AUC from 0 to 12 hours) at 2 weeks, 1 month and 2 months post-transplantation was 88%, 50% and 49% higher, respectively, than in 17 patients receiving concomitant therapy with cyclosporine. At all time points, patients in the sirolimus group had significantly higher dose-normalized mycophenolic acid AUC values than patients in the cyclosporine group. In addition, at months 1 and 2, white blood cell counts were significantly lower in the sirolimus group than in the cyclosporine group. Theoretically, the interaction may also occur with temsirolimus, a drug that is primarily metabolized to sirolimus in vivo.
MANAGEMENT: Mycophenolic acid plasma levels should be monitored more closely following initiation, discontinuation, or change of dosage of sirolimus or temsirolimus.
- Buchler M, Lebranchu Y, Beneton M, et al. "Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment." Clin Pharmacol Ther 78 (2005): 34-42
Generic Name: mycophenolate mofetil
Brand name: Cellcept, Myfortic, MMF
Synonyms: Mycophenolate mofetil (oral/injection), Mycophenolate
Generic Name: sirolimus
Brand name: Rapamune
Synonyms: Rapamune
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Mycophenolate Mofetil Capsules-Rapamune Tablets
- Mycophenolate Mofetil Capsules-Rapiflux
- Mycophenolate Mofetil Capsules-Rapivab
- Mycophenolate Mofetil Capsules-Raptiva
- Mycophenolate Mofetil Capsules-Rasagiline
- Mycophenolate Mofetil Capsules-Rasagiline Mesylate
- Rapamune (Sirolimus Tablets)-Mycophenolate Mofetil Injection
- Rapamune (Sirolimus Tablets)-Mycophenolate Mofetil Injection Solution
- Rapamune (Sirolimus Tablets)-Mycophenolate Mofetil Oral Suspension
- Rapamune (Sirolimus Tablets)-Mycophenolate mofetil oral/injection
- Rapamune (Sirolimus Tablets)-Mycophenolate Mofetil Tablets
- Rapamune (Sirolimus Tablets)-Mycophenolate sodium